CorMedix Inc. (NYSEAMERICAN:CRMD)’s share price traded up 8.9% on Tuesday . The stock traded as high as $0.62 and last traded at $0.61. 991,001 shares changed hands during trading, a decline of 57% from the average session volume of 2,314,391 shares. The stock had previously closed at $0.56.
Several equities analysts have commented on the company. Zacks Investment Research downgraded CorMedix from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd. HC Wainwright set a $3.00 price objective on CorMedix and gave the company a “buy” rating in a research report on Wednesday, August 15th.
CorMedix (NYSEAMERICAN:CRMD) last announced its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.10 million. CorMedix had a negative return on equity of 318.95% and a negative net margin of 16,300.49%.
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Featured Story: How to Use a Moving Average for Trading
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.